Is SYK a good stock to buy right now?

Based on our 6-factor quantitative model, STRYKER CORP (SYK) receives a "Reduce" rating with a composite score of 47.6/100. It is ranked #2,297 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 55/100, Momentum 39/100. The timing signal is "Bearish". This is quantitative analysis only — not investment advice.

What is the stock rating for SYK?

STRYKER CORP (SYK) has a "Reduce" rating and 2-star score. The composite score of 47.6 ranks it #2,297 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is SYK in?

STRYKER CORP operates in the Healthcare sector (Medical Equipment industry) with a market cap of $126.16 billion. It is classified as a large-cap stock.

Does SYK pay a dividend?

Yes, SYK pays a dividend with a current yield of 0.91%. For every $1,000 invested, you would receive approximately $9.10 in annual dividend income.

What is SYK's P/E ratio?

SYK has a trailing P/E ratio of 39.36x. The Healthcare sector average is 23.6x. This above-average P/E reflects growth expectations or premium valuation.

How profitable is SYK?

SYK's quality factor score is 50/100. Gross margin: 63.8%. ROE: 14.4% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is SYK valued compared to peers?

SYK's value factor score is 55/100 (higher = cheaper). Key multiples: P/E 39.4x, EV/EBITDA 30.5x. Valuation is roughly in line with peers.

What is SYK's debt level?

SYK's debt-to-equity ratio is 113%. Sector average: 32%. Moderate leverage is normal for established companies.

SYK has a beta of 0.66, meaning it is less volatile than the market. Stability score: 86/100.

Does SYK have high short interest?

SYK's short interest factor score is 33/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

SYK Stock Analysis: Reduce (Score 47.6/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
SYK	+0.00%	+2.30%	-5.44%	-3.51%	-2.65%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	+0.07%	-1.31%	-5.77%	-3.14%	-32.18%	-	-	-
Alpha vs Sector	+1.36%	+1.95%	-1.62%	+1.33%	-11.86%	-	-	-

Metric	SYK	Benchmark
P/E Ratio	39.4x	+67%
EV/EBITDA	30.5x	+381%
Price / Book	5.7x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
SYK STRYKER CORP	48	50	55	39	39.4x	14.4%	63.8%	13.8%	11.7%	113.0x	$126.2B

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.7%	0.7%	0.7%	0.7%
Operating Margin %	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
EBITDA Margin %	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
Net Margin %	0.1%	0.1%	0.1%	0.2%	0.1%	0.1%	0.1%	0.1%	0.3%	0.1%	0.1%
FCF Margin %	-13.5%	-	15.4%	-	-	-	19.4%	10.4%	15.0%	7.7%	12.6%
ROE %	0.1%	0.1%	0.1%	0.2%	0.1%	0.1%	0.1%	0.2%	0.3%	0.1%	0.2%
ROA %	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.0%	0.1%
ROIC %	9.2%	17.2%	9.5%	16.5%	13.5%	13.7%	7.3%	11.0%	11.2%	12.4%	13.0%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.6%

0.7%

Operating Margin %

0.2%

EBITDA Margin %

0.2%

Net Margin %

0.1%

0.2%

0.1%

0.3%

0.1%

FCF Margin %

-13.5%

15.4%

19.4%

10.4%

15.0%

7.7%

12.6%

ROE %

0.1%

0.2%

0.1%

0.2%

0.3%

0.1%

0.2%

ROA %

0.1%

0.0%

0.1%

0.0%

0.1%

ROIC %

9.2%

17.2%

9.5%

16.5%

13.5%

13.7%

7.3%

11.0%

11.2%

12.4%

13.0%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$23.4B	$25.1B	$22.6B	$20.5B	$18.4B	$17.1B	$14.4B	$14.9B	$13.6B	$12.4B	$11.3B	$9.9B
	—	$9.1B	—	$7.4B	$6.9B	$6.1B	—	—	—	—	—	—
	$15.0B	$16.1B	$14.4B	$13.1B	$11.6B	$11.0B	$9.1B	$9.7B	$8.9B	$8.2B	$7.5B	$6.6B
Gross Margin	63.8%	64.0%	63.9%	63.7%	62.8%	64.1%	63.1%	65.1%	65.7%	65.7%	66.3%	66.4%
	—	$8.7B	—	$7.1B	$6.5B	$6.4B	—	—	—	—	—	—
Research & Development	—	$1.6B	$1.5B	$1.4B	$1.5B	$1.2B	$984M	$971M	$862M	$787M	$715M	$625M
Depreciation	—	—	$1.1B	—	—	—	$812M	$778M	$723M	$642M	$546M	$397M
Total Operating Expenses	—	$11.2B	—	$9.2B	$8.7B	$8.4B	—	—	—	—	—	—
	$4.2B	$4.9B	$3.7B	$3.9B	$2.8B	$2.6B	$2.2B	$2.7B	$2.5B	$2.3B	$2.2B	$1.9B
EBIT	$4.2B	$4.9B	$3.7B	$3.9B	$2.8B	$2.6B	$2.2B	$2.7B	$2.5B	$2.3B	$2.2B	$1.9B
EBITDA	$4.2B	$4.9B	$4.5B	$3.9B	$2.8B	$2.6B	$2.8B	$3.3B	$3.1B	$2.7B	$2.5B	$2.1B
Operating Margin	17.8%	19.5%	16.3%	19.0%	15.4%	15.1%	15.5%	18.2%	18.6%	18.5%	19.2%	18.7%
EBITDA Margin	17.8%	19.5%	20.1%	19.0%	15.4%	15.1%	19.3%	22.4%	22.6%	21.7%	21.8%	21.4%
	—	$4.5B	—	$3.7B	$2.7B	$2.3B	—	—	—	—	—	—
Income Tax Expense	—	$1.3B	$499M	$508M	$325M	$287M	$355M	$479M	-$1.2B	$1.0B	$274M	$296M
	$3.2B	$3.2B	$3.0B	$3.2B	$2.4B	$2.0B	$1.6B	$2.1B	$3.6B	$1.0B	$1.6B	$1.4B
Net Margin	13.8%	12.9%	13.3%	15.4%	12.8%	11.7%	11.1%	14.0%	26.1%	8.2%	14.5%	14.5%
	$8.49	$8.49	$7.86	$8.34	$6.23	$5.29	$4.26	$5.57	$9.50	$2.73	$4.40	$3.82
Diluted EPS	$8.49	$8.40	$7.86	$8.25	$6.17	$5.21	$4.26	$5.57	$9.50	$2.73	$4.40	$3.82
Weighted Avg Basic	—	382M	—	380M	378M	377M	—	—	—	—	—	—
Weighted Avg Diluted	—	387M	—	384M	382M	382M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$23.4B

$25.1B

$22.6B

$20.5B

$18.4B

$17.1B

$14.4B

$14.9B

$13.6B

$12.4B

$11.3B

$9.9B

—

$9.1B

—

$7.4B

$6.9B

$6.1B

—

$15.0B

$16.1B

$14.4B

$13.1B

$11.6B

$11.0B

$9.1B

$9.7B

$8.9B

$8.2B

$7.5B

$6.6B

Gross Margin

63.8%

64.0%

63.9%

63.7%

62.8%

64.1%

63.1%

65.1%

65.7%

66.3%

66.4%

—

$8.7B

—

$7.1B

$6.5B

$6.4B

—

Research & Development

—

$1.6B

$1.5B

$1.4B

$1.5B

$1.2B

$984M

$971M

$862M

$787M

$715M

$625M

Depreciation

—

$1.1B

—

$812M

$778M

$723M

$642M

$546M

$397M

Total Operating Expenses

—

$11.2B

—

$9.2B

$8.7B

$8.4B

—

$4.2B

$4.9B

$3.7B

$3.9B

$2.8B

$2.6B

$2.2B

$2.7B

$2.5B

$2.3B

$2.2B

$1.9B

EBIT

$4.2B

$4.9B

$3.7B

$3.9B

$2.8B

$2.6B

$2.2B

$2.7B

$2.5B

$2.3B

$2.2B

$1.9B

EBITDA

$4.2B

$4.9B

$4.5B

$3.9B

$2.8B

$2.6B

$2.8B

$3.3B

$3.1B

$2.7B

$2.5B

$2.1B

Operating Margin

17.8%

19.5%

16.3%

19.0%

15.4%

15.1%

15.5%

18.2%

18.6%

18.5%

19.2%

18.7%

EBITDA Margin

17.8%

19.5%

20.1%

19.0%

15.4%

15.1%

19.3%

22.4%

22.6%

21.7%

21.8%

21.4%

—

$4.5B

—

$3.7B

$2.7B

$2.3B

—

Income Tax Expense

—

$1.3B

$499M

$508M

$325M

$287M

$355M

$479M

-$1.2B

$1.0B

$274M

$296M

$3.2B

$3.0B

$3.2B

$2.4B

$2.0B

$1.6B

$2.1B

$3.6B

$1.0B

$1.6B

$1.4B

Net Margin

13.8%

12.9%

13.3%

15.4%

12.8%

11.7%

11.1%

14.0%

26.1%

8.2%

14.5%

$8.49

$7.86

$8.34

$6.23

$5.29

$4.26

$5.57

$9.50

$2.73

$4.40

$3.82

Diluted EPS

$8.49

$8.40

$7.86

$8.25

$6.17

$5.21

$4.26

$5.57

$9.50

$2.73

$4.40

$3.82

Weighted Avg Basic

—

382M

—

380M

378M

377M

—

Weighted Avg Diluted

—

387M

—

384M

382M

—

STRYKER CORP (SYK) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does STRYKER CORP Do?

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan. STRYKER CORP (SYK) is classified as a large-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Kevin A. Lobo and employs approximately 51,000 people, headquartered in Kalamazoo, Michigan. With a market capitalization of $126.2B, SYK is one of the prominent companies in the Healthcare sector.

STRYKER CORP (SYK) Stock Rating — Reduce (April 2026)

As of April 2026, STRYKER CORP receives a Reduce rating with a composite score of 47.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.SYK ranks #2,297 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, STRYKER CORP ranks #271 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SYK Stock Price and 52-Week Range

STRYKER CORP (SYK) currently trades at $339.15. The stock gained $0.01 (0.0%) in the most recent trading session. The 52-week high for SYK is $404.87, which means the stock is currently trading -16.2% from its annual peak. The 52-week low is $328.23, putting the stock 3.3% above its annual trough. Recent trading volume was 1.7M shares, reflecting moderate market activity.

Is SYK Overvalued or Undervalued? — Valuation Analysis

STRYKER CORP (SYK) carries a value factor score of 55/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 39.36x, compared to the Healthcare sector average of 23.63x — a premium of 67%. The price-to-book ratio stands at 5.67x, versus the sector average of 2.75x. The price-to-sales ratio is 5.43x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, SYK trades at 30.50x EV/EBITDA, versus 6.34x for the sector.

Overall, SYK's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

STRYKER CORP Profitability — ROE, Margins, and Quality Score

STRYKER CORP (SYK) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 14.4%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 6.8% versus the sector average of -33.1%.

On a margin basis, STRYKER CORP reports gross margins of 63.8%, compared to 71.5% for the sector. The operating margin is 17.8% (sector: -66.1%). Net profit margin stands at 13.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 11.7% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

SYK Debt, Balance Sheet, and Financial Health

STRYKER CORP has a debt-to-equity ratio of 113.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.89x, suggesting adequate working capital coverage. Total debt on the balance sheet is $16.59B. Cash and equivalents stand at $3.26B.

SYK has a beta of 0.66, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for STRYKER CORP is 86/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

STRYKER CORP Revenue and Earnings History — Quarterly Trend

In TTM 2026, STRYKER CORP reported revenue of $23.44B and earnings per share (EPS) of $8.49. Net income for the quarter was $3.23B. Gross margin was 63.8%. Operating income came in at $4.17B.

In FY 2025, STRYKER CORP reported revenue of $25.12B and earnings per share (EPS) of $8.49. Net income for the quarter was $3.25B. Gross margin was 64.0%. Revenue grew 11.2% year-over-year compared to FY 2024. Operating income came in at $4.89B.

In Q3 2025, STRYKER CORP reported revenue of $6.06B and earnings per share (EPS) of $2.25. Net income for the quarter was $859M. Gross margin was 63.6%. Revenue grew 10.2% year-over-year compared to Q3 2024. Operating income came in at $1.14B.

In Q2 2025, STRYKER CORP reported revenue of $6.02B and earnings per share (EPS) of $2.32. Net income for the quarter was $884M. Gross margin was 63.8%. Revenue grew 11.1% year-over-year compared to Q2 2024. Operating income came in at $1.11B.

Over the past 8 quarters, STRYKER CORP has demonstrated a growth trajectory, with revenue expanding from $5.42B to $23.44B. Investors analyzing SYK stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SYK Dividend Yield and Income Analysis

STRYKER CORP (SYK) currently pays a dividend yield of 0.9%. At this yield, a $10,000 investment in SYK stock would generate approximately $$91.00 in annual dividend income. The net margin of 13.8% provides reasonable coverage for the dividend, though investors should monitor payout sustainability.

SYK Momentum and Technical Analysis Profile

STRYKER CORP (SYK) has a momentum factor score of 39/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 28/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 33/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

SYK vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, STRYKER CORP (SYK) ranks #271 out of 838 stocks based on the Blank Capital composite score. This places SYK in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SYK against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SYK vs S&P 500 (SPY) comparison to assess how STRYKER CORP stacks up against the broader market across all factor dimensions.

SYK Next Earnings Date

No upcoming earnings date has been announced for STRYKER CORP (SYK) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SYK? — Investment Thesis Summary

The quantitative profile for STRYKER CORP suggests caution. Momentum is weak at 39/100, a headwind for near-term performance. Low volatility (stability score 86/100) reduces downside risk.

In summary, STRYKER CORP (SYK) earns a Reduce rating with a composite score of 47.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SYK stock.

Related Resources for SYK Investors

Explore more research and tools: SYK vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SYK head-to-head with peers: SYK vs AZN, SYK vs SLGL, SYK vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds

Is Sandisk Corporation (SNDK) The Most Profitable Stock So Far In 2026?

Insulet Taps Mike Panos To Drive Omnipod Commercial Execution And Growth

ISRG Stock Down Nearly 20% YTD: Should You Buy, Hold or Sell?

Stryker is fully operational after cyberattack

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

STRYKER CORP (SYK) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does STRYKER CORP Do?

STRYKER CORP (SYK) Stock Rating — Reduce (April 2026)

SYK Stock Price and 52-Week Range

Is SYK Overvalued or Undervalued? — Valuation Analysis

STRYKER CORP Profitability — ROE, Margins, and Quality Score

SYK Debt, Balance Sheet, and Financial Health

STRYKER CORP Revenue and Earnings History — Quarterly Trend

SYK Dividend Yield and Income Analysis

SYK Momentum and Technical Analysis Profile

SYK vs Competitors — Healthcare Sector Ranking and Peer Comparison

SYK Next Earnings Date

Should You Buy SYK? — Investment Thesis Summary

Related Resources for SYK Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds

Is Sandisk Corporation (SNDK) The Most Profitable Stock So Far In 2026?

Insulet Taps Mike Panos To Drive Omnipod Commercial Execution And Growth

ISRG Stock Down Nearly 20% YTD: Should You Buy, Hold or Sell?

Stryker is fully operational after cyberattack